3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Conditions
Carcinoma, Hepatocellular
79
Carcinoma, Renal Cell
36
Neoplasms
35
Liver Neoplasms
22
Carcinoma, Non-Small-Cell Lung
7
Carcinoma
7
Neoplasm Metastasis
6
Melanoma
5
Thyroid Neoplasms
4
Kidney Neoplasms
4
Breast Neoplasms
3
Financial Stress
2
Vaccinia
1
Stomach Neoplasms
1
Patient Preference
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoma
1
Lung Neoplasms
1
Liver Diseases
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Insulin-Like Growth Factor I, Resistance To
1
Hypophosphatemia
1
Hepatitis C
1
Hepatitis B
1
Glioblastoma
1
Digestive System Neoplasms
1
Interventions
Standard of Care
2
COVID-19 Vaccines
2
regorafenib
1
proxalutamide
1
palbociclib
1
cilgavimab and tixagevimab drug combination
1
bemcentinib
1
acalabrutinib
1
Sorafenib
1
Sodium Chloride
1
Rabeprazole
1
NVX-CoV2373 adjuvated lipid nanoparticle
1
Janus Kinase Inhibitors
1
Interleukin-7
1
IBIO123
1
Gelsolin
1
COH04S1 COVID-19 vaccine
1
3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
1
2019-nCoV Vaccine mRNA-1273
1
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
1
1-palmityl-2-(4-carboxybutyl)-sn-glycero-3-phosphocholine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
COVID-19
×
Sorafenib
×
Clear all
NCT05594147
2023-11-07
ROCURS
Bayer
Completed
4,103 enrolled